Top

Current Osteoporosis Reports

Published in:

01-02-2019 | Osteonecrosis | Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

Hypoxia Signaling in the Skeleton: Implications for Bone Health

Authors: Clare E. Yellowley, Damian C. Genetos

Published in: Current Osteoporosis Reports | Issue 1/2019

Abstract

Purpose of Review

We reviewed recent literature on oxygen sensing in osteogenic cells and its contribution to development of a skeletal phenotype, the coupling of osteogenesis with angiogenesis and integration of hypoxia into canonical Wnt signaling, and opportunities to manipulate oxygen sensing to promote skeletal repair.

Recent Findings

Oxygen sensing in osteocytes can confer a high bone mass phenotype in murine models; common and unique targets of HIF-1α and HIF-2α and lineage-specific deletion of oxygen sensing machinery suggest differentia utilization and requirement of HIF-α proteins in the differentiation from mesenchymal stem cell to osteoblast to osteocyte; oxygen-dependent but HIF-α-independent signaling may contribute to observed skeletal phenotypes.

Summary

Manipulating oxygen sensing machinery in osteogenic cells influences skeletal phenotype through angiogenesis-dependent and angiogenesis-independent pathways and involves HIF-1α, HIF-2α, or both proteins. Clinically, an FDA-approved iron chelator promotes angiogenesis and osteogenesis, thereby enhancing the rate of fracture repair.

Monahan-Earley R, Dvorak AM, Aird WC. Evolutionary origins of the blood vascular system and endothelium. J Thromb Haemost. Wiley/Blackwell (10.1111); 2013;11 Suppl 1:46–66.

Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell. 2009;17:755–73.CrossRefPubMed

Hu C-J, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Tansey W, editor. Mol Biol Cell. 2007;18:4528–42.CrossRefPubMedPubMedCentral

Pawlus MR, Hu C-J. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal. 2013;25:1895–903.CrossRefPubMedPubMedCentral

Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem. American Society for Biochemistry and Molecular Biology. 2004;279:9899–904.

Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37:364–72.CrossRefPubMedPubMedCentral

Lin Q, Cong X, Yun Z. Differential Hypoxic Regulation of Hypoxia-Inducible Factors 1α and 2α. Mol Cancer Res. American Association for Cancer Research. 2011;9:757–65.

Stegen S, Carmeliet G. The skeletal vascular system – Breathing life into bone tissue. Bone. Elsevier. 2018;115:50–8.CrossRef

Brighton CT, Krebs AG. Oxygen tension of healing fractures in the rabbit. J Bone Joint Surg Am. 1972;54:323–32.CrossRefPubMed

10.

Harrison JS, Rameshwar P, Chang V, Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood. American Society of Hematology. 2002;99:394–4.

11.

Dodd JS, Raleigh JA, Gross TS. Osteocyte hypoxia: a novel mechanotransduction pathway. Am J Physiol. 1999;277:C598–602.CrossRefPubMed

12.

Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507:323–8.CrossRefPubMedPubMedCentral

13.

Sivaraj KK, Adams RH. Blood vessel formation and function in bone. Development. Oxford University Press for The Company of Biologists Limited; 2016;143:2706–2715.

14.

Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. Nature Publishing Group. 2014;508:269–73.

15.

Guo D, Keightley A, Guthrie J, Veno PA, Harris SE, Bonewald LF. Identification of osteocyte-selective proteins. Huber C, Huber L, editors. Proteomics. Wiley-Blackwell; 2010;10:3688–3698.

16.

Frikha-Benayed D, Basta Pljakic J, Majeska RJ, Schaffler MB. Regional differences in oxidative metabolism and mitochondrial activity among cortical bone osteocytes. Bone. Elsevier Inc. 2016;90:15–22.

17.

Mangiavini L, Merceron C, Araldi E, Khatri R, Gerard-O'Riley R, Wilson TL, et al. Loss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development. Dev Biol. 2014;393:124–36.CrossRefPubMedPubMedCentral

18.

Cheng S, Aghajanian P, Pourteymoor S, Alarcon C, Mohan S. Prolyl Hydroxylase Domain-Containing Protein 2 (Phd2) Regulates Chondrocyte Differentiation and Secondary Ossification in Mice. Sci Rep. 2016;6:35748.CrossRefPubMedPubMedCentral

19.

Weng T, Xie Y, Huang J, Luo F, Yi L, He Q, et al. Inactivation of Vhl in osteochondral progenitor cells causes high bone mass phenotype and protects against age-related bone loss in adult mice. J Bone Miner Res. 2014;29:820–9.CrossRefPubMedPubMedCentral

20••.

Wu C, Rankin EB, Castellini L, Alcudia JF, Fernandez-Alcudia J, LaGory EL, et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev. Cold Spring Harbor Lab; 2015;29:817–31. Deletion of individual PHD proteins in osteoprogenitors is insufficient to produce a high bone mass phenotype; high bone mass phenotypes can occur independent of changes in bone vascularity.

21••.

Cheng S, Xing W, Pourteymoor S, Mohan S. Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development. J Bone Miner Res. 2014;29:2276–86 Phd2 deletion in pre-osteoblasts decreases bone mass and microarchitecture, possibly through HIF-a-independent mechanisms that involve citamin C-induced osterix expression. CrossRefPubMed

22••.

Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007;117:1616–26 The first study to directly demonstrate genetic manipulation of oxygen-sensing in bone influences skeletal phenotype. CrossRefPubMedPubMedCentral

23•.

Shomento SH, Wan C, Cao X, Faugere M-C, Bouxsein ML, Clemens TL, et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J Cell Biochem. 2010;109:196–204 Demonstration that HIF-1a and HIF-2a in mature osteoblasts have common and unique influence on bone microarchitecture and vascularization. CrossRefPubMed

24••.

Stegen S, Stockmans I, Moermans K, Thienpont B, Maxwell PH, Carmeliet P, et al. Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nat Comms. Nature Publishing Group; 2018;9:2557. Osteocytic oxygen-sensing exerts profound effects on bone via epistatic inhibition of Sost expression.

25••.

Loots GG, Robling AG, Chang JC, Murugesh DK, Bajwa J, Carlisle C, et al. Vhl deficiency in osteocytes produces high bone mass and hematopoietic defects. Bone. 2018;116:307–14 Using an osteocytic cre driver, osteocytic deletion of Vhl influences bone mass through Wnt-dependent and -independent mechanisms. CrossRefPubMed

26.

Street J, Bao M, deGuzman L, Bunting S, Peale FV, Ferrara N, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA. 2002;99:9656–61.CrossRefPubMed

27.

Deckers MML, van Bezooijen RL, van der Horst G, Hoogendam J, Van Der Bent C, Papapoulos SE, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology. 2002;143:1545–53.CrossRefPubMed

28.

Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. Nature Publishing Group. 2014;507:376–80.

29.

Maes C, Araldi E, Haigh K, Khatri R, Van Looveren R, Giaccia AJ, et al. VEGF-independent cellautonomous functions of HIF-1α regulating oxygen consumption in fetal cartilage are critical for chondrocyte survival. J Bone Miner Res. Wiley-Blackwell. 2012;27:596–609.CrossRef

30.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–23.CrossRefPubMed

31.

Little R, Carulli J, Del Mastro R, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70:11–9.CrossRefPubMed

32.

Armstrong VJ, Muzylak M, Sunters A, Zaman G, Saxon LK, Price JS, et al. Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. J Biol Chem. 2007;282:20715–27.CrossRefPubMed

33.

Tu X, Rhee Y, Condon K, Bivi N, Allen MR, Dwyer D, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2011.

34.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006;281:23698–711.CrossRefPubMed

35.

Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009;24:171–8.CrossRefPubMed

36.

Kato M, Patel M, Levasseur R, Lobov I, Chang B, Glass D, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157:303–14.CrossRefPubMedPubMedCentral

37.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489–500.CrossRefPubMedPubMedCentral

38.

Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Research. 2005;15:928–35.CrossRefPubMedPubMedCentral

39.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537–43.CrossRefPubMed

40.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577–89.CrossRefPubMedPubMedCentral

41.

Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91–7.CrossRefPubMedPubMedCentral

42.

Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem. 2003;278:24113–7.CrossRefPubMed

43.

Nakanishi R, Shimizu M, Mori M, Akiyama H, Okudaira S, Otsuki B, et al. Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res. 2006;21:1713–21.CrossRefPubMed

44.

Bodine PVN, Zhao W, Kharode YP, Bex FJ, Lambert A-J, Goad MB, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004;18:1222–37.CrossRefPubMed

45.

Riddle RC, Leslie JM, Gross TS, Clemens TL. Hypoxia-inducible factor-1α protein negatively regulates load-induced bone formation. J Biol Chem. 2011;286:44449–56.CrossRefPubMedPubMedCentral

46.

Chen D, Li Y, Zhou Z, Xing Y, Zhong Y, Zou X, et al. Synergistic inhibition of Wnt pathway by HIF-1α and osteoblast-specific transcription factor osterix (Osx) in osteoblasts. Samant R, editor. PLoS ONE. Public Library of Science; 2012;7:e52948.

47.

Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010;110:457–67.PubMedPubMedCentral

48.

Peng J, Lai ZG, Fang ZL, Xing S, Hui K, Hao C, et al. Dimethyloxalylglycine prevents bone loss in ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis. Samant R, editor. PLoS ONE. Public Library of Science; 2014;9:e112744.

49.

Bouaziz W, Sigaux J, Modrowski D, Devignes C-S, Funck-Brentano T, Richette P, et al. Interaction of HIF1α and β-catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice. Proc Natl Acad Sci USA. National Academy of Sciences. 2016;113:5453–8.CrossRef

50.

Javaheri B, Stern AR, Lara N, Dallas M, Zhao H, Liu Y, et al. Deletion of a single β-catenin allele in osteocytes abolishes the bone anabolic response to loading. J Bone Miner Res. 2014;29:705–15.CrossRefPubMedPubMedCentral

51.

Tu X, Delgado-Calle J, Condon KW, Maycas M, Zhang H, Carlesso N, et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci USA. National Acad Sciences; 2015 :201409857.

52.

Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA. National Academy of Sciences; 2006;103:18154–9.

53.

Lee DC, Sohn HA, Park Z-Y, Oh S, Kang YK, Lee K-M, et al. A lactate-induced response to hypoxia. Cell. 2015;161:595–609.CrossRefPubMed

54.

Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 2009;15:682–9.CrossRefPubMedPubMedCentral

55.

Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruine AP, Baldwin HS, et al. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J. Federation of American Societies for Experimental Biology; 2010;24:4153–66.

56.

Xing W, Pourteymoor S, Mohan S. Ascorbic acid regulates osterix expression in osteoblasts by activation of prolyl hydroxylase and ubiquitination-mediated proteosomal degradation pathway. Physiological Genomics. American Physiological Society Bethesda, MD; 2011;43:749–57.

57.

Lahtinen T, Alhava EM, Karjalainen P, Romppanen T. The effect of age on blood flow in the proximal femur in man. Journal of Nuclear Medicine. 1981;22:966–72.PubMed

58.

Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone. 1987;8:157–64.CrossRefPubMed

59.

Prisby RD, Dominguez JM, Muller-Delp J, Allen MR, Delp MD. Aging and estrogen status: a possible endothelium-dependent vascular coupling mechanism in bone remodeling. Malaval L, editor. PLoS ONE. Public Library of Science; 2012;7:e48564.

60.

Senel K, Baykal T, Seferoglu B, Altas EU, Baygutalp F, Ugur M, et al. Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis. Arch Med Sci. Termedia. 2013;9:709–12.CrossRef

61.

Zhao Q, Shen X, Zhang W, Zhu G, Qi J, Deng L. Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone. Elsevier Inc. 2012;50:763–70.

62.

Komatsu D, Hadjiargyrou M. Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone. 2004;34:680–8.CrossRefPubMed

63.

Toupadakis CA, Wong A, Genetos DC, Chung D-J, Murugesh D, Anderson MJ, et al. Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair. J Orthop Res. 2012.

64.

Ward R. An update on disordered iron metabolism and iron overload. Hematology. 2010;15:311–7.CrossRefPubMed

65.

Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, et al. Activation of the hypoxiainducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci USA. 2008;105:686–91.CrossRefPubMed

66.

Donneys A, Deshpande SS, Tchanque-Fossuo CN, Johnson KL, Blough JT, Perosky JE, et al. Deferoxamine expedites consolidation during mandibular distraction osteogenesis. Bone. 2013;55:384–90.CrossRefPubMedPubMedCentral

67.

Shen X, Wan C, Ramaswamy G, Mavalli M, Wang Y, Duvall CL, et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res. 2009;27:1298–305.CrossRefPubMedPubMedCentral

68.

Stewart R, Goldstein J, Eberhardt A, Chu GT-MG, Gilbert S. Increasing vascularity to improve healing of a segmental defect of the rat femur. J Orthop Trauma. 2011;25:472–6.CrossRefPubMedPubMedCentral

69.

Fan L, Li J, Yu Z, Dang X, Wang K. Hypoxia-inducible factor prolyl hydroxylase inhibitor prevents steroid-associated osteonecrosis of the femoral head in rabbits by promoting angiogenesis and inhibiting apoptosis. PLoS ONE. Public Library of Science; 2014;9:e107774. Pre-clinical evidence that small molecule PHD antagonists can mitigate avascular necrosis.

70•.

Rankin EB, Wu C, Khatri R, Wilson TLS, Andersen R, Araldi E, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149:63–74 Vhl deletion in osteoprogenitors causes a high bone mass and HIF-dependent polycythemia. CrossRefPubMedPubMedCentral

71.

Rabadi S, Udo I, Leaf DE, Waikar SS, Christov M. Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Renal Physiol. 2018;314:F132–9.CrossRefPubMed

72.

Flamme I, Ellinghaus P, Urrego D, Kruger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. Jelkmann WEB, editor. PLoS ONE. Public Library of Science; 2017;12:e0186979.

73.

Clinkenbeard EL, Hanudel MR, Stayrook KR, Appaiah HN, Farrow EG, Cass TA, et al. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica. Haematologica. 2017;102:e427–30.CrossRefPubMed

74.

Zhang Q, Doucet M, Tomlinson RE, Han X, Quarles LD, Collins MT, et al. The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 2016;4:175–6.

75.

Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. Springer US. 2015;16:165–74.CrossRef

76.

Johnson EO, Soultanis K, Soucacos PN. Vascular anatomy and microcirculation of skeletal zones vulnerable to osteonecrosis: vascularization of the femoral head. Orthop Clin North Am. 2004;35:285–91–viii.

77.

Hong JM, Kim T-H, Chae S-C, Koo K-H, Lee YJ, Park EK, et al. Association study of hypoxia inducible factor 1alpha (HIF1alpha) with osteonecrosis of femoral head in a Korean population. Osteoarthr Cartil. 2007;15:688–94.CrossRefPubMed

78.

Hong JM, Kim TH, Kim HJ, Park EK, Yang EK, Kim SY. Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med. Nature Publishing Group. 2010;42:376–85.CrossRef

79.

Radke S, Battmann A, Jatzke S, Eulert J, Jakob F, Schutze N. Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res. Wiley-Blackwell. 2006;24:945–52.CrossRef

80.

Weinstein RS, Hogan EA, Borrelli MJ, Liachenko S, O'Brien CA, Manolagas SC. The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology. 2017;158:3817–31.CrossRefPubMedPubMedCentral

81.

Fowler TW, Acevedo C, Mazur CM, Hall-Glenn F, Fields AJ, Bale HA, et al. Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci Rep. 2017;7:44618.CrossRefPubMedPubMedCentral

82.

Wickham N, Crawford A, Carney AS, Goss AN. Bisphosphonate-associated osteonecrosis of the external auditory canal. J Laryngol Otol. Cambridge University Press; 2013;127 Suppl 2:S51–3.

83.

McCadden L, Leonard CG, Primrose WJ. Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature. J Laryngol Otol. Cambridge University Press. 2018;132:372–4.CrossRef

84.

Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893–7.PubMed

85.

Xiong H, Wei L, Hu Y, Zhang C, Peng B. Effect of alendronate on alveolar bone resorption and angiogenesis in rats with experimental periapical lesions. Int Endod J. Wiley/Blackwell (10.1111); 2010;43:485–91.

86.

Soki FN, Li X, Berry J, Koh A, Sinder BP, Qian X, et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem. Wiley-Blackwell. 2013;114:67–78.CrossRef

87.

Zhang L, Wang T, Chang M, Kaiser C, Kim JD, Wu T, et al. Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model. J Bone Miner Res. Wiley-Blackwell. 2017;32:1870–83.CrossRef

88.

Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. Wiley-Blackwell. 2010;25:2427–37.CrossRef

89.

Isowa S, Shimo T, Ibaragi S, Kurio N, Okui T, Matsubara K, et al. PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anticancer Res. 2010;30:2755–67.PubMed

90.

Prisby R, Guignandon A, Vanden-Bossche A, Mac-Way F, Linossier M-T, Thomas M, et al. Intermittent PTH(1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J Bone Miner Res. 2011;26:2583–96.CrossRefPubMed

91.

Rhee Y, Park S-Y, Kim YM, Lee S, Lim SK. Angiogenesis inhibitor attenuates parathyroid hormone-induced anabolic effect. Biomed. Pharmacother. 2009;63:63–8.CrossRefPubMed

92.

Frey JL, Stonko DP, Faugere M-C, Riddle RC. Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone. Bone Res. 2014;2:14005.CrossRefPubMedPubMedCentral

93.

Riddle RC, Clemens TL. Bone Cell Bioenergetics and Skeletal Energy Homeostasis. Physiological Reviews. 2017;97:667–98.CrossRefPubMedPubMedCentral

Title: Hypoxia Signaling in the Skeleton: Implications for Bone Health
Authors: Clare E. Yellowley
Damian C. Genetos
Publication date: 01-02-2019
Publisher: Springer US
Keyword: Osteonecrosis
Published in: Current Osteoporosis Reports / Issue 1/2019
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-019-00500-6

At a glance: The STEP trials

Springer Medicine

Hypoxia Signaling in the Skeleton: Implications for Bone Health

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2019

RAGE Signaling in Skeletal Biology

Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments

Stopping Denosumab

Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing